Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

Next Previous
Trial Profile

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixekizumab (Primary) ; Guselkumab
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms IXORA-R
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 21 Mar 2023 Results of post-hoc pooled analysis assessing NPF treatment targets in the overall population, and biologic-experienced and -naive subpopulations across IXORA-R, IXORA-S, integrated UNCOVER-2-3 presented at the American Academy of Dermatology annual Meeting 2023
  • 21 Mar 2023 Results(n=54) comparing the early effects of IXE and GUS on psoriasis pathway genes in lesions between baseline and weeks 1, 2, and 4, presented at the American Academy of Dermatology annual Meeting 2023
  • 13 Mar 2022 Results assessing simultaneous skin and nail clearance in patients with psoriasis across five head-to-head trials (IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, and SPIRIT-H2H) comparing ixekizumab with other biologics, published in the Dermatology and Therapy.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top